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Abstract
Gold nanoparticles (AuNP) have been widely used for drug delivery and have recently been 
explored for applications in cancer immunotherapy. Although AuNPs are known to accumulate 
heavily in the spleen, the particle distribution within immune cells has not been thoroughly 
studied. Here, we characterize the cellular distribution of Cy5 labeled 50 nm AuNPs within the 
immune populations of the spleen from naïve and tumor bearing mice using flow cytometry. 
Surprisingly, approximately 30% of the detected AuNPs were taken up by B cells at 24 hours, with 
about 10% in granulocytes, 18% in dendritic cells, and 8% in T cells. In addition, 3% of the 
particles were detected within myeloid derived suppressor cells, an immune suppressive 
population that could be targeted for cancer immunotherapy. Furthermore, we observed that, over 
time, the particles traveled from the red pulp and marginal zone to the follicles of the spleen. 
Taking into consideration that the particle cellular distribution did not change at 1, 6 and 24 hours, 
it is highly suggestive that the immune populations carry the particles and migrate through the 
spleen instead of the particles migrating through the tissue by cell-cell transfer. Finally, we 
observed no difference in particle distribution between naïve and tumor bearing mice in the spleen 
and detected nanoparticles within 0.7% of dendritic cells of the tumor microenvironment. Overall, 
these results can help inform and influence future AuNP delivery design criteria including future 
applications for nanoparticle-mediated immunotherapy.
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1. Introduction
Gold nanoparticles (AuNPs) have been applied in a number of cancer treatment modalities 
including drug delivery, gene therapy, and photothermal ablation.[1–4] AuNPs can be easily 
synthesized and can be modified with a variety of materials including drugs,[2] polymers,[5] 
targeting ligands,[6] and nucleic acids.[7] Recently, AuNPs have been used for cancer 
immunotherapy as delivery vehicles for cancer antigens and immune adjuvants.[8, 9] Gold 
nanoparticles are well suited for immune cell targeting, for they are naturally taken up by the 
immune system upon in vivo injection, and it has been shown that AuNP mediated delivery 
enhances the effect of tumor antigens[8, 10, 11] and immune adjuvants.[9, 12]
Yet, despite numerous studies focused on the biodistribution of gold nanoparticles, very little 
has been done to understand the cellular level distribution of nanoparticles in vivo, 
particularly within cells of the immune system. Biodistribution studies have focused on gold 
accumulation at the organ level, demonstrating that AuNPs show the highest accumulation 
in the liver and spleen.[13–16] Shah et al. observed that gold nanoparticles traversed from the 
red pulp to the white pulp of the spleen over time but did not identify the immune cells 
involved in particle uptake.[17] In the liver, Bartneck and colleagues observed 30 fold higher 
accumulation of gold nanorods in immature macrophages as opposed to Kupffer cells; given 
that immature macrophages can cause inflammatory liver injury, their finding emphasizes 
the importance of identifying immune cell subsets that take up nanoparticles.[18] Therefore, 
in this study, we sought to characterize the distribution of gold nanoparticles within the 
major immune populations of the spleen, which is both the largest immune organ and one of 
the sites of highest AuNP accumulation.
In the spleen, arteries enter the red pulp--a framework of collagen and reticular fibers 
containing fibroblasts, macrophages, and reticular cells-- and branch into smaller 
arterioles.[19, 20] The blood progresses into the venous sinuses, and most of it passes through 
the white pulp, which consists of the periarteriolar lymphoid sheath (PALS), the marginal 
zone, and the follicles. The PALS, also known as the T-cell zone, surrounds the arterioles 
and is composed of T lymphocytes that interact with dendritic cells and migrating B cells. 
The follicles are mainly composed of B cells but also contain follicular dendritic cells and T 
cells. Finally, the marginal zone is an efficient area of blood borne particulate capture, where 
marginal zone macrophages, dendritic cells, and B cells can act as antigen presenting cells 
(APCs) and migrate into the follicles to interact with T cells.[19, 20]
Characterizing the distribution of AuNPs within the spleen is valuable for understanding 
nanoparticle immune effects and for developing nanoparticle mediated immunotherapies. 
For instance, Yen and colleagues have shown that AuNPs in the 2 nm to 40 nm size range 
can induce macrophage expression of inflammatory genes for TNFα and IL-6 in vitro.[21] 
Sumbayev et al., in turn, show that AuNPs can suppress IL-1β dependent inflammatory 
responses in vitro and in vivo in a size dependent manner.[22] Finally, Tsai and colleagues 
have demonstrated that treatment with particles in the 4 to 45 nm range can inhibit 
macrophage toll like receptor 9 responses to CpG, with smaller particles having a stronger 
effect than larger particles.[23] AuNP mediated therapies have progressed into clinical 
trials,[24] and thus it is important to further understand AuNP interactions with the immune 
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system. On the other hand, nanoparticle uptake by immune cells could be exploited in the 
development of immunotherapies,[25, 26] again illustrating the importance of characterizing 
such interactions. Here, we assessed the splenic distribution of gold nanoparticles in naïve 
and tumor bearing mice and showed that AuNPs distributed widely across splenic immune 
cells, including B cells, T cells, granulocytes, dendritic cells, myeloid derived suppressor 
cells, and macrophages.
2. Results and Discussion
2.1 Gold nanoparticle characterization
50 nm gold nanoparticles coated with polyethylene glycol (PEG) were chosen as a design 
representative of particles that would be typically used in cancer applications. The size, 
shape, and surface coating can be optimized to prolong nanoparticle circulation so that the 
nanoparticles can reach the target tumor site.[13, 14, 27] Hydrophilic methylated polyethylene 
glycol (mPEG) coating protects particles from opsonization and subsequent blood clearance, 
and Perrault and colleagues have shown that PEGylated particles with core sizes in the 20 to 
50 nm range are optimal for increased blood half-life.[28] Additionally, it has been shown 
that 50 nm is the optimal size for mammalian cell uptake of AuNPs.[29] Finally, particles in 
this size range have been used in a number of applications including photothermal 
therapy,[30] siRNA delivery,[31] vaccine delivery,[11] and drug delivery.[32]
Therefore, 50 nm gold colloid nanoparticles conjugated with Cy5-terminated PEG-SH 
(5,000 MW) were used for our studies. Conjugation of the PEG on the gold surface was 
confirmed by observing a shift in absorbance when compared to the absorbance of citrate 
stabilized 50 nm gold colloids (Supplementary Figure 1). The spectrum and the red color of 
the solution also indicated that the particles did not aggregate. The hydrodynamic diameter 
and zeta potential of the Cy5-PEGylated particles were also comparable to that of normal 
mPEG coated AuNPs, thus indicating that incorporating Cy5 onto PEG-AuNPs did not alter 
the particle characteristics (Supplementary Table 1). The PEG coating increased the 
diameter of the particle by ~ 30 nm compared to the citrate stabilized AuNPs.
2.2 Particle injection does not alter splenic cell distribution
Naïve C57BL/6J mice were injected with approximately 1.5 × 1011 particles in PBS, a dose 
in the range of previous studies.[33–37] Mice that did not receive particle injections were 
used as controls. After 1, 6, and 24 hours, the spleens were harvested and stained for the 
following immune cell populations and markers: CD3+ (T cells), B220+ (B cells), CD11b+ 
(monocytes and macrophages), CD11b+, Gr-1+ (myeloid derived suppressor cells), Gr-1+ 
(granulocytes), and CD11c+ (dendritic cells). Although there is widespread expression of 
CD21 and CD23 markers, CD21++CD23− populations are indicative of marginal zone B 
cells while CD21+CD23+ populations are indicative of follicular B cells (Table 1). [38–40] 
The spleen is mainly composed of CD3+ T cells and B220+ B cells (Figure 1). The myeloid 
populations of CD11b+ monocytes and macrophages, CD11b+Gr-1+ myeloid-derived 
suppressor cells (MDSCs), Gr-1+ granulocytes, and CD11c+ dendritic cells each comprise 
less than 10% of splenocytes. We also noted that the nanoparticle injections caused no 
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significant differences in the percentages of each population when compared to untreated 
controls.
2.3 Particles travel from the red pulp to the white pulp of the spleen over time
Histological samples of the spleen were stained with hematoxolin and eosin, and the gold 
nanoparticles were visualized by dark field microscopy, while their location was correlated 
with bright field microscopy of the tissue (Figure 2). Untreated spleens displayed only 
normal tissue scattering and none of the characteristic scattering from nanoparticles. At 1 
hour post-injection, the particles appeared and localized mainly within the red pulp and 
marginal zone of the spleen (red circles) (Figure 2B). At 6 hours, the particles were still 
present in the marginal zone and red pulp, but they were also visible within the follicles (red 
arrows) (Figure 2C). Finally, at 24 hours, the particles were mainly located at the center of 
the follicles while remaining particles were still visible in the red pulp and marginal zone 
(Figure 2D). These observations indicated that most of the particles moved from the red pulp 
to the marginal zone and to the middle of the follicle, and were consistent with previous 
findings by Shah and colleagues.[17] To further ensure that the presence of Cy5 does not 
affect the distribution of the particles, this experiment was repeated with AuNPs coated with 
unlabeled mPEG (Supplementary Figure 3). The particles showed the same pattern over 
time, with most of the particles appearing in the red pulp at 1 hour and progressing to the 
follicles by 24 hours. Therefore, the presence of Cy5 had negligible effect on the 
distribution.
2.4 Nanoparticle signal is widely distributed but mainly detected in B cells
To identify the Cy5 positive cells in mice that received nanoparticle injections, gates for Cy5 
events were established in untreated mice. The percentage of marker+Cy5+ in the spleen 
(e.g., B220+Cy5+ divided by all events) was compared between treated and untreated mice 
for the immune populations mentioned in Table 1 and at all time points (Supplementary 
Figure 2). All percentages were significantly different than control (p < 0.01), showing that 
the Cy5+ events were from the injected nanoparticles.
Next, we evaluated the distribution of Cy5 events within the immune cells, i.e. the percent of 
the nanoparticle dose that is in each immune population. For instance, the percent of dose 
detected within B220+ cells is given by B220+Cy5+ events divided by all Cy5+ events. The 
distribution of the nanoparticle Cy5 dose in the respective populations at 1, 6, and 24 hours 
post-injection are shown in Figure 3. At 1 hour, the highest percent of Cy5 events was found 
within B220+ B cells (32%), and this percentage is significantly higher than that found in 
CD3+ T cells (12%, p < 0.0001), CD11b+ monocytes and macrophages (7.7%, p < 0.0001), 
Gr-1+ granulocytes (15.8%, p < 0.0001), CD11c+ dendritic cells (13.6%, p<0.0001), 
CD11b+Gr-1+ MDSCs (3%, p < 0.0001), and CD21++CD23− cells (22.8%, p < 0.0001). This 
finding indicates that the nanoparticles were detected mainly in B cells 1 hour after 
injection. A detectable percentage of the events (13.6%) was present in dendritic cells 
despite the low percentage of CD11c+ cells in the spleen. A measureable percentage was 
also found in other low percentage populations such as Gr-1+ granulocytes and 
CD11b+Gr-1+ MDSCs, with 15.8% and 3% of the signal detected within these populations, 
respectively.
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At 6 hours, 58.5% of the Cy5 signal was detected in B220+ cells, and the percentage within 
this population was significantly higher than that found in all other populations (p < 0.0276) 
(Figure 3B). The trend was similar at 24 hours with the highest percentages of Cy5 dose 
found within B220+CD21++CD23−, CD21+CD23+, and CD11c+ cells (Figure 3C). 
Interestingly, the percentage in B cells increased significantly from 1 hour to 6 hours, going 
from 32% to 58.5% (p = 0.0372) (Figure 3D). The percentage was then significantly 
decreased at 24 hours to 31.4% (p = 0.0415). In turn, the dose in Gr-1+ cells significantly 
decreased from 15.8% at 1 hour to 7.3% at 6 hours. The only other change over time was 
observed in CD21+CD23+ cells, where the percentage dropped from 36.6% at 6 hours to 
17.7% at 24 hours (p=0.0065). The cause of these changes was not evident and may be the 
result of fluorescence differences over time or experimental variability.
There were no other significant differences in Cy5 distribution within each population, and 
more importantly, the pattern of distribution remained the same across the different time 
points. The histology images showed that the particles traveled through the spleen over time, 
and given that the distribution pattern did not change in the 24 hour period, the particles 
were likely to have migrated with the cells instead of transferring from one cell population 
to another. The movement of the particles may result from cells such as marginal zone B 
cells and dendritic cells taking up nanoparticles and then migrating to the follicle.[20] Of 
course, mechanisms of cellular transfer such as trogocytosis[41] and exocytosis could also be 
at play, and these potential mechanisms merit further study. The presence of nanoparticles 
within the marginal zone is consistent with their association with MDSCs, as MDSCs have 
been shown to be localized within the marginal zone.[42] The markers used here are not 
exclusive to one population, and there may be overlap within subsets of dendritic cells, B 
cells, and other immune populations, but the results illustrate that the nanoparticles were 
distributed across a range of major immune cells including CD3+ T cells, B220+ B cells, 
CD11c+ dendritic cells, CD11b+ monocytes and macrophages, CD11b+Gr-1+ MDSCs, and 
Gr-1+ granulocytes. Cy5+ signal within CD21++CD23− cells may indicate involvement of 
marginal zone B cells while CD21+CD23+ cells may indicate follicular B cells;[38, 39] 
however, uptake by those subsets needs to be further explored in future studies.
Various biodistribution studies have shown that despite AuNP modifications aimed at 
avoiding spleen and liver uptake, such as PEG coating, targeting ligands, and size and 
charge variations, a substantial portion of the injected dose will inevitably be retained in the 
spleen.[13] Studies show a wide range of spleen accumulation, with reports varying between 
10% to over 60% of the injected dose reaching the spleen.[27, 34, 43] The consequences of 
such accumulation are still unclear. A previous study in rats by Terentyuk and colleagues has 
shown that 50 nm PEGylated gold nanoparticles can cause blood congestion in the red pulp 
and damage to the white pulp.[44] Balasubramanian et al. studied AuNP effects on gene 
expression in rat spleens and reported down-regulation of genes associated with healing and 
other defense responses.[36] Furthermore, as aforementioned, there is ongoing study into the 
effects of AuNPs on inflammatory responses in vitro and in vivo. [21–23] In this study, the 
histology slides were reviewed by an independent pathologist, and the analysis showed that 
nanoparticle treatment caused no inflammation or signs of splenotoxicity such as apoptosis 
or atrophy. However, the particle treatment resulted in vascular congestion as well as red 
pulp expansion, indicated by an increased presence of histiocytes, lymphocytes, and 
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megakaryocytes. The results presented here elucidate which splenic immune populations 
interact with nanoparticles after intravenous injection as well as how the spleen reacts to a 
typically used nanoparticle design and thus can be used to inform future studies on AuNP 
immune effects.
2.5 Percent of each immune population positive for Cy5 signal
Next, we examined the percentage of each cell population that was Cy5 positive (Figure 4). 
At 1 hour post injection, approximately 2.9% of CD21++CD23− cells were positive for Cy5, 
significantly higher than the percentages within all other populations (p < 0.0086). This 
higher proportion as well as the localization of nanoparticles in the marginal zone (Figure 2) 
again suggests that the particles are taken up by marginal zone B cells. The involvement of 
marginal zone B cells is likely, for this population in mice can uptake blood borne 
particulates that have been coated with opsonins.[40] AuNPs are known to be opsonized once 
entering the blood stream[13, 14] and may thus be recognized by marginal zone B cells in the 
spleen.
By 24 hours, about 2.5% of CD11c+ dendritic cells, 3.1% of Gr-1+ granulocytes, and 1.4% 
of MDSCs were positive for Cy5. Interestingly, these percentages were comparable to the 
percentage of B220+ B cells positive for Cy5, even though the percentage of B cells in the 
spleen is significantly higher. There were no significant differences in the percentages of 
cells associated with Cy5 over time, again suggesting that the nanoparticles did not transfer 
from one cell population to another but instead remained within respective populations that 
migrate over time. Overall, the distribution of the nanoparticle dose and the percentage of 
each cell population involved indicate that nanoparticles primarily interact with B cells, T 
cells, granulocytes, and dendritic cells in the spleen. Importantly, a measureable percentage 
of the nanoparticle Cy5 signal is detected within MDSCs. Given the comparable percentage 
of cells positive for Cy5 between myeloid cells and B220+ B cells, the myeloid populations 
may be more efficient at capturing nanoparticles and could potentially be targets for 
nanoparticle mediated drug delivery.
2.6 Nanoparticle distribution is unaffected in a B16F10 melanoma model
To assess whether these distribution patterns would be the same in a disease model, we 
tested the nanoparticles in mice bearing a B16F10 melanoma tumor. C57BL/6J mice were 
implanted with subcutaneous B16F10 tumors and injected with the same dose of particles 
once the tumors reached approximately 1 cm2 in size. The spleens were harvested after 24 
hours and analyzed as before. The distribution of splenic populations showed a significant 
drop in CD3+ T cells when compared to non-tumor bearing mice (p=0.0324) (Figure 5A). 
Interestingly, there was no significant difference in either Cy5 events distribution or the 
percent of cells positive for Cy5 when compared to naïve mice examined 24 hours after 
nanoparticle injection (Figures 5B and 5C). Therefore, the nanoparticle distribution within 
major immune cells does not change in tumor bearing mice.
It is worth noting that approximately 22% of Cy5 events were found in CD11c+ dendritic 
cells, with 15% in Gr-1+ granulocytes and 4.8% in CD11b+Gr-1+ MDSCs of tumor bearing 
mice. Importantly, the nanoparticles reach these populations by passive targeting, without 
Almeida et al. Page 6
Small. Author manuscript; available in PMC 2015 February 26.
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
AHFormatter
EVALUATION
AH Formatter V6.2 MR6 (Evaluation)  http://www.antennahouse.com/
the aid of ligands or antibodies specific for these cells. The involvement of these populations 
indicates that they could be potential targets for nanoparticle mediated immunotherapy. The 
particles’ high association with dendritic cells makes them promising vehicles for delivery 
of immune antigens and adjuvants.[10, 25] In addition, Niikura and colleagues recently 
reported that 40 nm spherical AuNPs can act as adjuvants for vaccines, for they can induce 
antigen specific antibody production in vivo and bone marrow derived dendritic cell 
inflammatory responses in vitro.[11] The involvement of granulocytes and myeloid derived 
suppressor cells is also important because granulocytic and myeloid progenitor populations 
in the spleen have been shown to provide cancer sites with tumor associated macrophages 
and neutrophils that promote tumor growth.[45] In addition, it has been well established that 
MDSCs are recruited to the tumor microenvironment and suppress anti-tumor immune 
responses by inhibiting T cell activity and promoting antigen tolerance.[42, 46] Targeting 
MDSCs for immune modulation is a promising immune therapy approach that is a subject of 
ongoing work.[47, 48] Given the association of MDSCs with nanoparticle signal, this 
population could potentially be targeted with AuNP mediated delivery of drugs that have 
been shown to suppress MDSC activity, such as sunitinib[49] or CpG.[48, 50]
We also assessed particle distribution in the immune cells of the tumor microenvironment, 
characterizing Cy5 events within CD8+ cytotoxic T cells, CD4+ helper T cells, CD11c+ 
dendritic cells, CD11b+ monocytes and macrophages, and CD11b+Gr-1+ MDSCs. To ensure 
that Cy5 events were accurately captured, the percent of Marker+Cy5+ cells in the entire 
tumor was calculated in untreated mice and in mice treated with AuNPs, as was done in the 
spleen. The percentage of CD11c+Cy5+ cells was significantly higher than in untreated 
controls (p=0.0376), indicating that the Cy5 events were due to the particle injection (Figure 
6). This difference was not significant in the other immune populations, and, as such, we 
could only detect the nanoparticle Cy5 signal within CD11c+ dendritic cells. Approximately 
1.8% of the tumor microenvironment was composed of CD11c+ dendritic cells, and about 
0.01% of all cells in the microenvironment were CD11c+Cy5+. However, 36 +/− 10% of all 
Cy5 events detected were found within CD11c+ cells, indicating that a large portion of the 
AuNP dose that reaches the tumor resides within dendritic cells. Additionally, 0.7 +/− 0.2% 
of CD11c+ cells were positive for Cy5. We could not account for the remaining Cy5 signal, 
but the tumor microenvironment is a complex milieu of inflammatory cells, fibroblasts, 
blood vessels, and tumor cells,[51, 52] and the distribution of AuNPs within the various cell 
types merits further work. Overall, nanoparticles reach dendritic cells both in the spleen and 
the tumor, again illustrating their potential for targeting this population.
3. Conclusions
This study elucidates the immune cell distribution of 50 nm PEG coated gold nanoparticles 
in the spleen, showing that the nanoparticles associate with a range of immune populations. 
The signal from the particles is most highly present in B cells, granulocytes, dendritic cells, 
and T cells, and it appears that the signal remains associated with these populations in the 1 
hour to 24 hour range examined in this study. The particles show high association with 
CD21++CD23− cells, indicating uptake by marginal zone B cells, but these observations 
need to be further explored. The anatomical location of the particles vary with time, with 
AuNPs mainly localizing to the red pulp and marginal zone at 1 hour and appearing in the 
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marginal zone and follicle between 6 and 24 hours after injection. The consistent particle 
distribution over time observed using flow cytometry suggests that the particles may migrate 
with the immune cells as they traverse the spleen. It is possible that marginal zone B cells 
and dendritic cells take up particles and migrate into the follicle following uptake. Finally, 
the distribution patterns observed did not vary between tumor bearing and non-tumor 
bearing mice, and a detectable percentage of Cy5 signal was present in dendritic cells, 
granulocytes, and MDSCs of the spleens of tumor bearing mice. In addition, AuNPs can be 
detected in the dendritic cells of the tumor microenvironment. These populations and others 
could potentially be targeted for cancer immunotherapy, and the distribution characterized 
here could prove informative for future nanoparticle toxicity studies.
4. Experimental Section
Nanoparticle conjugation
50 nm citrate stabilized gold nanoparticles (Ted Pella) were conjugated with 5,000 MW 
polyethylene glycol terminated with Cy5 purchased from NanoCS, MA. Absorbance was 
measured using the Cary 60 UV-Vis (Agilent Technologies), hydrodynamic diameter was 
measured using a 90 Plus Particle Size Analyzer (Brookhaven), and the zeta potential was 
measured with a Zen 3600 Zetasizer (Malvern Instruments).
Animal studies and tumor model
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were kept in the Animal Resource 
Facility of Rice University, and the study was approved by the Institutional Animal Care and 
Use Committee. The particles were suspended in PBS and injected intravenously at a 
concentration of 1.5×1011 particles per injection. After 1 (n=6), 6 (n=6), or 24 hours (n=5), 
the mice were euthanized, and the spleens were harvested by passing through a 70 µm cell 
strainer. The cell suspension underwent red blood cell lysis (Sigma) prior to staining with 
antibodies. The following antibodies were obtained from BD Biosciences and used for flow 
cytometry analysis: anti-CD11c PE, anti-B220 PE, anti-CD3 FITC, anti-CD11b PE, anti-
Gr-1 FITC, anti-CD23 PE, and anti-CD21 FITC. The stained samples were then analyzed 
using a BD FACSCantoII flow cytometer.
For the tumor study, mice were injected subcutaneously with 5×105 B16-F10 melanoma 
cells in PBS (n=7). Once the tumors reached approximately 1 cm2 in size, the mice received 
an intravenous injection of nanoparticles. Tumor bearing mice that did not receive particle 
injections were used as controls (n=4). The spleens were harvested after 24 hours and 
analyzed as previously described. The tumors were also harvested, passed through a cell 
strainer, and treated with red blood cell lysis buffer. The following antibodies were used for 
flow cytometry: anti-CD8 PE, anti-CD3 FITC, anti-CD11c PE, anti-CD11b PE, and anti-
GR-1 FITC (BD Biosciences). The B16F10 cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin/
streptomycin. The cells were kept at 37°C and 5% CO2.
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Histological images
Spleen tissue was formalin fixed and dehydrated in ethanol prior to sectioning. The sections 
were prepared as 3 µm paraffin-embedded slides stained with hematoxylin and eosin (H&E) 
at the Baylor College of Medicine Pathology Core. Brightfield images were taken with a 
Zeiss Axioskop 2 Plus microscope, and darkfield images were taken with a Cytoviva 
enhanced darkfield microscope.
Statistics
All comparisons were done using a significance level of α=0.05, and the Tukey’s HSD test 
on JMP Pro Software.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Percentage of immune populations in the spleens of mice that were untreated or harvested 1, 
6 or 24 hours after AuNP intravenous injection.
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Figure 2. 
H&E bright field and dark field images of murine spleens at middle and edges of the 
follicles. A) Untreated spleen. B) Spleen 1 hour following AuNP injection. C) Spleen 6 
hours after AuNP injection. D) Spleen 24 hours after AuNP injection. Images are 
representative of 3 samples. (Scale bar = 100 µm)
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Figure 3. 
Distribution of AuNP associated Cy5 positive signal within immune populations at different 
time points. A) 1 hour, B) 6 hours, and C) 24 hours after AuNP intravenous injection. D) 
Distribution of Cy5 signal within immune populations at all time points. *, p<0.05. **, 
p<0.01. ***, p<0.0001.
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Figure 4. 
Percent of each immune population associated with AuNP Cy5 signal A) 1 hour, B) 6 hours, 
and C) 24 hours after AuNP injection. D) Percent of each immune population associated 
with AuNP Cy5 signal at all time points. *, p<0.05. **, p<0.01. ***, p<0.0001.
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Figure 5. 
Comparison of particle distribution in the spleen between tumor free and tumor bearing 
mice. A) Percent of each immune population in the spleens of tumor free and tumor bearing 
mice. B) Distribution of Cy5 signal within each immune population 24 hours after AuNP 
injection in tumor free and tumor bearing mice. C) Percent of each immune population 
associated with Cy5 signal 24 hours after AuNP injection in tumor free and tumor bearing 
mice. *, p<0.05.
Almeida et al. Page 16
Small. Author manuscript; available in PMC 2015 February 26.
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
AHFormatt r
EVALUATION
AH Formatter V6.2 MR6 (Evaluation)  http://www.antennahouse.com/
Figure 6. 
Percentage of CD11c positive and particle positive cells (CD11c+Cy5+) in the tumor 
microenvironment. *, p < 0.05.
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Table 1
Immune populations analyzed by flow cytometry.
Marker Immune population
CD3 T cells
B220 B cells
CD21++CD23− Suggestive of marginal zone B cells
CD21+CD23+ Suggestive of follicular B cells
CD11b Monocytes and macrophages
CD11b+Gr-1+ Myeloid-derived suppressor cells
Gr-1 Granulocytes
CD11c Dendritic cells
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